Milestone Pharmaceuticals Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
Quebec, Canada
Business Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8, H4M 2X6
Mailing Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8, H4M 2X6
Phone
(514) 336-0444
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$73.05M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 3 Initial insider ownership report | March 23, 2026 | View on SEC |
| 10-K Annual financial report | March 20, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 4/A Insider transaction amendment | February 5, 2026 | View on SEC |
| 4/A Insider transaction amendment | February 5, 2026 | View on SEC |
| 4/A Insider transaction amendment | February 5, 2026 | View on SEC |
| 4/A Insider transaction amendment | February 5, 2026 | View on SEC |
| 4/A Insider transaction amendment | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
Annual Reports
10-K
March 20, 2026
- U.S. FDA approval of CARDAMYST™ (etripamil) in late 2024 for PSVT, making it the first and only self-administered therapy.
- Advanced Phase 3 clinical trials for etripamil in Atrial Fibrillation, targeting a potentially larger market.
Insider Trading
STRONG SELL
5 insiders
12 recent transactions
View Insider Trading Dashboard
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.